An increasing number of studies have suggested the combination of multiple biomarkers, such as integrating p-tau217, GFAP, Aβ42/40 and various other blood biomarkers, to enhance the specificity of early diagnosis of AD (Janelidze et al., 2023; Milà-Alomà et al., 2022). This evidence concerns the gene GFAP and Alzheimer disease.